

To: Business Editor
【For Immediate Release】



李氏大藥廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司

Lee's Zhaoke Pharmaceutical Ranks Second in 2014 for Number of Declared New Drug Application

【Hong Kong – 26 February 2015】 Lee's Pharmaceutical Holdings Limited (“Lee's Pharm” or the “Group”; Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, is pleased to announce that its wholly-owned subsidiary operating in China, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke Pharmaceutical”), ranked second in 2014 in the number of its declared New Drug Application (NDA) .

According to the Drug Evaluation Report 2014 recently published by Insight - China Pharma Data, the China Food and Drug Administration's Center for Drug Evaluation (CDE) reviewed and accepted a total of 8,880 new applications for drug registration in 2014, marking a new high. Among the 8,880 applications, 7,807 were accepted as chemical drug applications, which was also a record high. By contrast, the number of accepted Chinese medicine applications fell compared with previous years and was the lowest in five years. As for the accepted number of biological product applications, the figure was relatively stable. In 2014, the CDE handled a total of 2,321 new accepted applications for new chemical drugs, marking the highest total in five years. The applications represented a 46% increase compared to the same period last year.

With respect to Insight - China Pharma Data, CDE reviewed and accepted a total of 155 new applications for category 1.1 chemical drugs (new chemical entity-NCE) in 2014. The applications involved a total of 64 NCE and majority fell into the category of anti-cancer drugs. Among the figures, 61 of them were IND and three of them were NDA. The most IND of NCE submitted by one company is four and Zhaoke Pharmaceutical ranked second in the country with three IND of NCE submission.

Dr. Benjamin Li, Executive Director and Chief Executive Officer of the Group, was encouraged by the news and said, “New drug discovery and development is the key to our Group's sustainable growth. Driven both by increasing market demand in Chinese medical industry and investment in healthcare, we will continue to accelerate the pace of developing drugs and explore new areas for future growth. At the same time, we remain confident that we will maintain sustainable growth for our core products. On account of our thriving operations and solid financial condition, the Group will seize market opportunities and adapt to the times, delivering to our shareholders the very best rewards.”

- The End -

博達浩華國際財經傳訊集團

Porda Havas International Finance Communications Group

Units 2009-2018, 20/F, Shui On Centre, 6-8 Harbour Road, Wanchai, HK 香港灣仔港灣道6-8號瑞安中心20樓2009-2018室
T : (852) 3150 6788 F : (852) 3150 6728

www.pordahavas.com

About INSIGHT - China Pharma Data

INSIGHT - China Pharma Data is China's largest integrated medical information platform. It was created by a professional team serving doctors, medical institutions, pharmaceutical practitioners and specialists in the life and science fields. It provides comprehensive and professional information and consultation services for pharmaceutical research and development, marketing, project cooperation and industry data analysis.

To learn more about INSIGHT - China Pharma Data, please visit <http://db.dxy.cn>.

About Lee's Pharmaceutical Holdings Limited

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular diseases, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspires to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information about Lee's Pharm is available at www.leespharm.com.

This press release is issued by **Porda Havas International Finance Communications Group** on behalf of **Lee's Pharmaceutical Holdings Limited**. For enquiries, please contact:

Porda Havas International Finance Communications Group

Keely Chan	+852 3150-6760	keely.chan@pordahavas.com
Cherry Cheung	+852 3150-6773	cherry.cheung@pordahavas.com
Sophie Zhang	+852 3150-6742	sophie.zhang@pordahavas.com
Mandy Zhang	+852 3150-6765	mandy.zhang@pordahavas.com

Fax: +852 3150-6728